Rein Therapeutics Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $72.6M
- Price
- $0.792
- % Change (Daily % change from the live per-ticker quote feed.)
- +6.19%
- Volume
- 332.8K
About
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
Quick stats
Shares outstanding86.3M
Computed float81.2M
Float / shares94.2%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001420565
Websitehttp://www.reintx.com
AI Summary
AI-generated1/12
standardbullishearnings
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Rein Therapeutics reported that its Phase 2 RENEW trial of LTI-03 in IPF has surpassed 25% enrollment and remains on track to report interim data in the second half of 2026.
The company successfully completed an oversubscribed $57.5 million public offering, bringing its cash position to $43.6 million and extending its operational runway into the first quarter of 2028.
For the second quarter, the net loss narrowed to $6.4 million compared to $6.8 million in the prior year, driven by lower R&D and G&A expenses.